Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 10Gynecologic 5Plasma cell 3Breast 3Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2Gastrointestinal 2Thoracic 1Other 1NET 1Endocrine 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasm Metastasis 1Endometrial Neoplasms 1Breast Neoplasms, Male 1Advanced Glioblastoma 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × TIC10 compound × Breast × Clear all
NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 15 charts
BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03733119 2022-03-10

ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer

University of Wisconsin, Madison

Phase 2 Terminated
4 enrolled 10 charts
Breast

Triple Negative Breast Neoplasms

NCT02038699 2021-04-30

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Jazz Pharmaceuticals

Phase 1/2 Withdrawn
BreastCNSGastrointestinalThoracic

Advanced Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡